Trevi Therapeutics Inc TRVI:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/03/24 EDT
3.02UNCH (UNCH)
Volume
1,991
Close
3.02quote price arrow up+0.01 (+0.33%)
Volume
24,791
52 week range
0.97 - 4.00
Loading...
  • Open3.02
  • Day High3.12
  • Day Low2.98
  • Prev Close3.01
  • 52 Week High4.00
  • 52 Week High Date03/21/24
  • 52 Week Low0.97
  • 52 Week Low Date11/27/23

Key Stats

  • Market Cap208.26M
  • Shares Out68.96M
  • 10 Day Average Volume0.15M
  • Dividend-
  • Dividend Yield-
  • Beta0.91
  • YTD % Change125.37

KEY STATS

  • Open3.02
  • Day High3.12
  • Day Low2.98
  • Prev Close3.01
  • 52 Week High4.00
  • 52 Week High Date03/21/24
  • 52 Week Low0.97
  • 52 Week Low Date11/27/23
  • Market Cap208.26M
  • Shares Out68.96M
  • 10 Day Average Volume0.15M
  • Dividend-
  • Dividend Yield-
  • Beta0.91
  • YTD % Change125.37

RATIOS/PROFITABILITY

  • EPS (TTM)-0.29
  • P/E (TTM)-10.29
  • Fwd P/E (NTM)-7.68
  • EBITDA (TTM)-33.80M
  • ROE (TTM)-30.59%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)0.19%

EVENTS

  • Earnings Date05/07/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Trevi Therapeutics Inc

 

Profile

MORE
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed k-opioid receptor agonist and...
David Meeker M.D.
Non-Executive Chairman of the Board
Jennifer Good
President, Chief Executive Officer, Director
Lisa Delfini CPA
Chief Financial Officer
Address
195 Church St Fl 14
New Haven, CT
06510-2009
United States

Top Peers

SYMBOLLASTCHG%CHG
ATOS
Atossa Therapeutics Inc
1.66+0.14+9.21%
ABOS
Acumen Pharmaceuticals Inc
3.49+0.01+0.29%
LENZ
LENZ Therapeutics Inc
16.46+0.05+0.30%
XFOR
X4 Pharmaceuticals Inc
1.15+0.07+6.48%
CADL
Candel Therapeutics Inc
9.02+0.59+7.00%